Weight loss showdown: GLP-1 drugs vs. surgery for pelvic floor health
NCT ID NCT07175805
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 200 women who are either taking GLP-1 weight loss drugs or undergoing bariatric surgery. Researchers want to see how these treatments change pelvic floor symptoms like incontinence and prolapse. Participants do not need to have any pelvic floor symptoms to join. The goal is to help doctors recommend the best weight loss option for women with these issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonist (e.g., semaglutide) or bariatric surgery
What this could lead to
If successful, this could help doctors choose the best weight loss treatment for women with pelvic floor issues.
What could go wrong
This is an observational study, not a treatment trial. It will only measure symptoms, not prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOWER URINARY TRACT SYMPTOMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hartford Hospital
Hartford, Connecticut, 06106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••